MARKET DEFINITION

Bacillus anthrax is the bacteria that causes anthrax (B. anthrax). The majority of cattle who contract it do so by consuming soil-borne spores. Humans often get anthrax through touching leather or wool goods from diseased animals or by breathing anthrax spores from these materials. Consuming raw meat from diseased animals might also make them sick. It is unknown how anthrax spreads from person to person. Depending on the clinical characteristics, appropriate specimens for PCR, gram stain, and cultures from blood, pleural fluid, ulcer site, CSF, and stool are included in the differential diagnosis of anthrax.

MARKET DYNAMICS

One of the key factors fueling the expansion of the market for anthrax treatments is the rise in the number of anthrax cases throughout the world. The hazard of exposure to Bacillus anthrax among civilian populations and armed personnel as well as the increase in financial assistance provided to researchers for the development of innovative therapies both contribute to the market expansion. The market is also influenced by the rise of public-private partnerships and the expansion of research and development programs that facilitate unique discoveries for cutting-edge and successful treatments. However, the high cost of the process and therapy as well as onerous government restrictions for product approval are anticipated to restrain the market's expansion for anthrax treatment.

REPORT SCOPE

The report titled “Global Anthrax Treatment Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Anthrax Treatment market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Anthrax Treatment market with a strong Distribution Channel on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Anthrax Treatment Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

MARKET SEGMENTATION

The Global Anthrax Treatment Market is segmented based on type, drug type, end-user, distribution channel and region. Based on type, the market has been segmented into Cutaneous Anthrax, Inhalation Anthrax, Gastrointestinal Anthrax and Injection Anthrax, whereas based on drug type, the market comprises Ciprofloxacin (Cipro), Doxycycline (Vibramycin) and Levofloxacin. Based on end-user, the market has been segmented into Government Organization, Hospitals, Academic and Research Institutes and Others, whereas, the distribution channel segmentation includes Hospitals Pharmacies, Retail Pharmacies, E-commerce, Drug Stores and Others.

COMPETITION LANDSCAPE

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Anthrax Treatment market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Anthrax Treatment market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Anthrax Treatment market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Anthrax Treatment industry in the past three years.

Key players in the Global Anthrax Treatment Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

• Altimune Inc.
• Elusys Therapeutics, Inc.
• Emergent BioSolutions, Inc.
• Porton Biopharma
• Pfizer Inc.
• Glaxo SmithKline Pharmaceuticals Ltd
• Elusys Therapeutics, Inc.
• Emergent BioSolutions, Inc
• PharmAthene, Inc.
• Teva Pharmaceutical Industries Ltd
• Novartis AG
• Bayer AG

COVID-19 IMPACT ANALYSIS ON GLOBAL ANTHRAX TREATMENT MARKET

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED

1. What is the current size of the global Anthrax Treatment market?
2. What will be the growth rate of the market over the forecast period?
3. Who are the key manufacturers/vendors in the Anthrax Treatment market space?
4. What are the major market opportunities and market risks faced by the market?
5. What is the impact of COVID-19 on the market?
6. What are the revenue, sales, and price analysis of the top manufacturers in this market?
7. What are the key outcomes of Porter's five forces model?
8. Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:

• The report offers comprehensive data on the Anthrax Treatment market elaborating on the current state and future growth prospects both globally and regionally
• It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth
• The report offers deep-dive insights into each market segment and critical factors responsible for its growth
• The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position
• The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions
• Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope
• The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity
 
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
 
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Type Trends
3.2.2. Drug Type Trends
3.2.3. End Users Trends
3.2.4. Distribution Channel Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Anthrax Treatment Market
3.6. COVID-19 Impact Assessment in Anthrax Treatment Market
3.6.1. Impact Assessment on Global Anthrax Treatment Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape
 
Chapter 4. Global Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
4.1. Global Anthrax Treatment Market Share, By Type, 2017 - 2028 (USD Million)
4.1.1. Cutaneous Anthrax
4.1.2. Inhalation Anthrax
4.1.3. Gastrointestinal Anthrax
4.1.4. Injection Anthrax
 
Chapter 5. Global Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
5.1. Global Anthrax Treatment Market Share, By Drug Type, 2017 - 2028 (USD Million)
5.1.1. Ciprofloxacin (Cipro)
5.1.2. Doxycycline (Vibramycin)
5.1.3. Levofloxacin
 
Chapter 6. Global Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
6.1. Global Anthrax Treatment Market Share, By End Users, 2017 - 2028 (USD Million)
6.1.1. Government Organization
6.1.2. Hospitals
6.1.3. Academic and Research Institutes
6.1.4. Others
 
Chapter 7. Global Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
7.1. Global Anthrax Treatment Market Share, By Distribution Channel, 2017 - 2028 (USD Million)
7.1.1. Hospitals Pharmacies
7.1.2. Retail Pharmacies
7.1.3. E-commerce
7.1.4. Drug Stores
7.1.5. Others
 
Chapter 8. Global Anthrax Treatment Market Overview, By Geography, 2017 - 2028 (USD Million)
8.1. Global Anthrax Treatment Market Share, By Geography, 2017 - 2028 (USD Million)
8.1.1. Market Size and Projections, by Countries, 2017 - 2028 (USD Million)
8.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)
 
Chapter 9. North America Anthrax Treatment Market Overview, By Countries, 2017 - 2028 (USD Million)
9.1. North America Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
9.1.1. Market size and projections, 2017 - 2028 (USD Million)
9.1.2. North America Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
9.1.3. North America Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
9.1.4. North America Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
9.1.5. North America Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2. North America Anthrax Treatment Market Overview, By Countries, 2017 - 2028 (USD Million)
9.2.1. U.S. Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
9.2.1.1. U.S. Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
9.2.1.2. U.S. Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
9.2.1.3. U.S. Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
9.2.1.4. U.S. Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.2. Canada Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
9.2.2.1. Canada Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
9.2.2.2. Canada Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
9.2.2.3. Canada Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
9.2.2.4. Canada Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.3. Mexico Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
9.2.3.1. Mexico Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
9.2.3.2. Mexico Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
9.2.3.3. Mexico Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
9.2.3.4. Mexico Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 10. Europe Anthrax Treatment Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. Europe Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market size and projections, 2017 - 2028 (USD Million)
10.1.2. Europe Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
10.1.3. Europe Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
10.1.4. Europe Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
10.1.5. Europe Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2. Europe Anthrax Treatment Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. Germany Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. Germany Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
10.2.1.2. Germany Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
10.2.1.3. Germany Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
10.2.1.4. Germany Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.2. France Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. France Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
10.2.2.2. France Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
10.2.2.3. France Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
10.2.2.4. France Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.3. UK Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. UK Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
10.2.3.2. UK Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
10.2.3.3. UK Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
10.2.3.4. UK Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.4. Italy Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
10.2.4.1. Italy Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
10.2.4.2. Italy Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
10.2.4.3. Italy Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
10.2.4.4. Italy Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.5. Spain Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
10.2.5.1. Spain Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
10.2.5.2. Spain Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
10.2.5.3. Spain Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
10.2.5.4. Spain Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.6. NORDIC Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
10.2.6.1. NORDIC Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
10.2.6.2. NORDIC Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
10.2.6.3. NORDIC Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
10.2.6.4. NORDIC Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.7. Russia and CIS Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
10.2.7.1. Russia and CIS Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
10.2.7.2. Russia and CIS Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
10.2.7.3. Russia and CIS Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
10.2.7.4. Russia and CIS Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.8. Rest of Europe Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
10.2.8.1. Rest of Europe Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
10.2.8.2. Rest of Europe Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
10.2.8.3. Rest of Europe Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
10.2.8.4. Rest of Europe Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 11. Asia Pacific Anthrax Treatment Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. Asia Pacific Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market size and projections, 2017 - 2028 (USD Million)
11.1.2. Asia Pacific Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
11.1.3. Asia Pacific Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
11.1.4. Asia Pacific Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
11.1.5. Asia Pacific Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2. Asia Pacific Anthrax Treatment Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. India Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. India Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.1.2. India Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
11.2.1.3. India Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
11.2.1.4. India Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.2. China Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. China Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.2.2. China Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
11.2.2.3. China Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
11.2.2.4. China Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.3. Japan Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. Japan Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.3.2. Japan Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
11.2.3.3. Japan Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
11.2.3.4. Japan Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.4. ASEAN Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
11.2.4.1. ASEAN Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.4.2. ASEAN Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
11.2.4.3. ASEAN Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
11.2.4.4. ASEAN Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.5. South Korea Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
11.2.5.1. South Korea Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.5.2. South Korea Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
11.2.5.3. South Korea Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
11.2.5.4. South Korea Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.6. Australia Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
11.2.6.1. Australia Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.6.2. Australia Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
11.2.6.3. Australia Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
11.2.6.4. Australia Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.7. Rest of Asia Pacific Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
11.2.7.1. Rest of Asia Pacific Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.7.2. Rest of Asia Pacific Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
11.2.7.3. Rest of Asia Pacific Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
11.2.7.4. Rest of Asia Pacific Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 12. South America Anthrax Treatment Market Overview, By Countries, 2017 - 2028 (USD Million)
12.1. South America Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
12.1.1. Market size and projections, 2017 - 2028 (USD Million)
12.1.2. South America Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
12.1.3. South America Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
12.1.4. South America Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
12.1.5. South America Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2. South America Anthrax Treatment Market Overview, By Countries, 2017 - 2028 (USD Million)
12.2.1. Brazil Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
12.2.1.1. Brazil Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
12.2.1.2. Brazil Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
12.2.1.3. Brazil Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
12.2.1.4. Brazil Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.2. Argentina Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
12.2.2.1. Argentina Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
12.2.2.2. Argentina Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
12.2.2.3. Argentina Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
12.2.2.4. Argentina Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.3. Rest of South America Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
12.2.3.1. Rest of South America Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
12.2.3.2. Rest of South America Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
12.2.3.3. Rest of South America Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
12.2.3.4. Rest of South America Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 13. Middle East & Africa Anthrax Treatment Market Overview, By Countries, 2017 - 2028 (USD Million)
13.1. Middle East & Africa Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
13.1.1. Market size and projections, 2017 - 2028 (USD Million)
13.1.2. Middle East & Africa Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
13.1.3. Middle East & Africa Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
13.1.4. Middle East & Africa Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
13.1.5. Middle East & Africa Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
13.2. Middle East & Africa Anthrax Treatment Market Overview, By Countries, 2017 - 2028 (USD Million)
13.2.1. GCC Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
13.2.1.1. GCC Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
13.2.1.2. GCC Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
13.2.1.3. GCC Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
13.2.1.4. GCC Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
13.2.2. South Africa Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
13.2.2.1. South Africa Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
13.2.2.2. South Africa Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
13.2.2.3. South Africa Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
13.2.2.4. South Africa Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
13.2.3. Rest of Middle East & Africa Anthrax Treatment Market Overview, 2017 - 2028 (USD Million)
13.2.3.1. Rest of Middle East & Africa Anthrax Treatment Market Overview, By Type, 2017 - 2028 (USD Million)
13.2.3.2. Rest of Middle East & Africa Anthrax Treatment Market Overview, By Drug Type, 2017 - 2028 (USD Million)
13.2.3.3. Rest of Middle East & Africa Anthrax Treatment Market Overview, By End Users, 2017 - 2028 (USD Million)
13.2.3.4. Rest of Middle East & Africa Anthrax Treatment Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 14. Competitive Landscape
14.1. Competitive Environment, 2021
14.2. Strategic Framework
14.2.1. Partnership/Collaborations/Agreement
14.2.2. Expansion
14.2.3. Mergers & Acquisitions
14.2.4. New Product Development
 
Chapter 15. Key Vendor Analysis
15.1. Altimune Inc.
15.1.1. Business Overview
15.1.2. Product Benchmarking
15.1.3. Financial Data
15.1.4. Strategic Overview
15.1.5. Key Developments
15.1.6. SWOT Analysis
15.2. Elusys Therapeutics, Inc.
15.2.1. Business Overview
15.2.2. Product Benchmarking
15.2.3. Financial Data
15.2.4. Strategic Overview
15.2.5. Key Developments
15.2.6. SWOT Analysis
15.3. Emergent BioSolutions, Inc.
15.3.1. Business Overview
15.3.2. Product Benchmarking
15.3.3. Financial Data
15.3.4. Strategic Overview
15.3.5. Key Developments
15.3.6. SWOT Analysis
15.4. Porton Biopharma
15.4.1. Business Overview
15.4.2. Product Benchmarking
15.4.3. Financial Data
15.4.4. Strategic Overview
15.4.5. Key Developments
15.4.6. SWOT Analysis
15.5. Pfizer Inc.
15.5.1. Business Overview
15.5.2. Product Benchmarking
15.5.3. Financial Data
15.5.4. Strategic Overview
15.5.5. Key Developments
15.5.6. SWOT Analysis
15.6. Glaxo SmithKline Pharmaceuticals Ltd
15.6.1. Business Overview
15.6.2. Product Benchmarking
15.6.3. Financial Data
15.6.4. Strategic Overview
15.6.5. Key Developments
15.6.6. SWOT Analysis
15.7. Elusys Therapeutics, Inc.
15.7.1. Business Overview
15.7.2. Product Benchmarking
15.7.3. Financial Data
15.7.4. Strategic Overview
15.7.5. Key Developments
15.7.6. SWOT Analysis
15.8. Emergent BioSolutions, Inc
15.8.1. Business Overview
15.8.2. Product Benchmarking
15.8.3. Financial Data
15.8.4. Strategic Overview
15.8.5. Key Developments
15.8.6. SWOT Analysis
15.9. PharmAthene, Inc.
15.9.1. Business Overview
15.9.2. Product Benchmarking
15.9.3. Financial Data
15.9.4. Strategic Overview
15.9.5. Key Developments
15.9.6. SWOT Analysis
15.10. Teva Pharmaceutical Industries Ltd
15.10.1. Business Overview
15.10.2. Product Benchmarking
15.10.3. Financial Data
15.10.4. Strategic Overview
15.10.5. Key Developments
15.10.6. SWOT Analysis
15.11. Novartis AG
15.11.1. Business Overview
15.11.2. Product Benchmarking
15.11.3. Financial Data
15.11.4. Strategic Overview
15.11.5. Key Developments
15.11.6. SWOT Analysis
15.12. Bayer AG
15.12.1. Business Overview
15.12.2. Product Benchmarking
15.12.3. Financial Data
15.12.4. Strategic Overview
15.12.5. Key Developments
15.12.6. SWOT Analysis
 
Chapter 16. Future Outlook of the Market